CN209137002U - A kind of medicinal balloon - Google Patents
A kind of medicinal balloon Download PDFInfo
- Publication number
- CN209137002U CN209137002U CN201820640738.8U CN201820640738U CN209137002U CN 209137002 U CN209137002 U CN 209137002U CN 201820640738 U CN201820640738 U CN 201820640738U CN 209137002 U CN209137002 U CN 209137002U
- Authority
- CN
- China
- Prior art keywords
- balloon
- coating
- sacculus
- middle section
- proximal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 claims abstract description 160
- 239000011248 coating agent Substances 0.000 claims abstract description 127
- 238000000576 coating method Methods 0.000 claims abstract description 127
- 229940079593 drug Drugs 0.000 claims abstract description 80
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims description 5
- 230000003902 lesion Effects 0.000 abstract description 52
- 208000037803 restenosis Diseases 0.000 abstract description 12
- 230000008859 change Effects 0.000 abstract description 8
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 6
- 206010070863 Toxicity to various agents Diseases 0.000 abstract description 6
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 230000036262 stenosis Effects 0.000 abstract description 5
- 208000037804 stenosis Diseases 0.000 abstract description 5
- 230000003319 supportive effect Effects 0.000 abstract 1
- 238000010586 diagram Methods 0.000 description 14
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 13
- 239000004677 Nylon Substances 0.000 description 9
- 206010020718 hyperplasia Diseases 0.000 description 9
- 229920001778 nylon Polymers 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- WMYIFEPOLLNNBZ-UHFFFAOYSA-N 2-(2-hexoxy-2-oxoethyl)-2-hydroxybutanedioic acid Chemical compound CCCCCCOC(=O)CC(O)(C(O)=O)CC(O)=O WMYIFEPOLLNNBZ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000005639 Lauric acid Substances 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 150000003851 azoles Chemical class 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 3
- 229960002603 iopromide Drugs 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 150000002895 organic esters Chemical class 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 229940045136 urea Drugs 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- PESZCXUNMKAYME-UHFFFAOYSA-N Citroflex A-4 Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)C(C(C)=O)C(=O)OCCCC PESZCXUNMKAYME-UHFFFAOYSA-N 0.000 description 2
- 201000000057 Coronary Stenosis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical group OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 2
- 229960001025 iohexol Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WWXUGNUFCNYMFK-UHFFFAOYSA-N Acetyl citrate Chemical compound CC(=O)OC(=O)CC(O)(C(O)=O)CC(O)=O WWXUGNUFCNYMFK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1075—Balloon catheters with special features or adapted for special applications having a balloon composed of several layers, e.g. by coating or embedding
Abstract
The utility model discloses a kind of medicinal balloons, and including sacculus and positioned at the medication coat of the balloon surface, the medication coat includes drug and excipient；The medication coat includes proximal end coating, middle section coating and distal end coating, the load medicine density for carrying medicine density and being greater than the middle section coating of one in the proximal end coating and the distal end coating, the load medicine density for carrying medicine density and being not less than the middle section coating of another one.When treating stent restenosis lesion, pressurising is carried out for lesion characteristic selection medicinal balloon, medicinal balloon plays a supportive role, the big coating part for carrying medicine density is adjacent to the Serious Stenosis lesion of proximal end or distal end, selectivity improves medicament contg, the stenosis rate in serious change region is reduced, while reducing the total drug content of whole section of lesion, reduces body drug toxicity and adverse reaction.
Description
Technical field
The utility model relates to the field of medical instrument technology, narrow again in bracket for treating more specifically to one kind
Narrow medicinal balloon.
Background technique
Cardiovascular and cerebrovascular disease has become the big cause of the death that beats the world.Currently, being directed to the treatment method of ischemic heart disease
There are mainly three types of: using the Primary Care of drug, the operative treatment of progress coronary artery bypass grafting, by being placed in coronary artery bracket etc. to solve
Except the interventional therapy of coronary stenosis.Above-mentioned several treatment methods all achieve apparent effect in terms for the treatment of coronary artery stenosis
Fruit, but respectively there are still some significant problems.
Wherein, percutaneous transluminal coronary stent implantation is that support system is transported to target area, sacculus by way of puncturing intervention
Expansion release bracket, struts stenotic lesion blood vessel, restores blood supply, treat ischemic heart disease.However bracket is chronically at human body
It is interior, body can be stimulated to generate immunological rejection, smooth muscle cell hyperplasia causes intimal thickening, causes lumen to be lost, drop
Low lumen patency rate, and then blood supply is influenced, threaten the life and health safety of patient.For this purpose, being directed to intrastent restenotic lesions, need
Secondary intervention being carried out to patient to perform the operation, supporting restenotic lesions blood vessel again, recovery blood flow is unimpeded, saves patient vitals.
At present clinically for stent restenosis lesion therapeutic modality mainly include traditional PTA sacculus, intravascular stent and
The modes such as medicinal balloon.
Medicinal balloon covers the drug for inhibiting smooth muscle cell hyperplasia on the surface of traditional PTA sacculus, drop
Low restenosis incidence, but current medicinal balloon is too low for intrastent restenotic lesions administration medicine content, then to smooth
The inhibiting effect of myocyte is insufficient, lumen patency rate decline at a specified future date；Medicament contg is excessively high, then the drug total amount of body will cause poison
Property reaction.
In conclusion when using medicinal balloon, how more effectively to inhibit bracket close for intrastent restenotic lesions
End and/or distal end smooth muscle cell hyperplasia improve lumen patency rate at a specified future date, guarantee therapeutic effect, while reducing whole section of disease
The total drug content of change, and then reduce body drug toxicity and adverse reaction, it is that current those skilled in the art are urgently to be solved
Problem.
Utility model content
In view of this, the purpose of this utility model is to provide a kind of medicinal balloon for treating in-stent restenosis, the medicine
After the structure design of object sacculus can efficiently solve existing medicinal balloon implantation human body, given for intrastent restenotic lesions
Medicine, medicament contg is too low, insufficient to the inhibiting effect of smooth muscle cell, lumen patency rate decline at a specified future date；Medicament contg is excessively high, then
The problem of drug total amount of body will cause toxic reaction.
In order to achieve the above object, the utility model provides the following technical solutions:
A kind of medicinal balloon, including sacculus and positioned at the medication coat of the balloon surface, the medication coat includes medicine
Object and excipient；The medication coat includes proximal end coating, middle section coating and distal end coating, the proximal end coating and the distal end
The load medicine density for carrying medicine density and being greater than the middle section coating of one, the load medicine density of another one are not less than the middle section in coating
The load medicine density of coating.
Preferably, in said medicine sacculus, the proximal end coating, the middle section coating and the distal end coating order connect
It connects, is distributed in the sacculus outer surface.
Preferably, in said medicine sacculus, the drug be taxol, Docetaxel, rapamycin, rapamycin and
One or more of its azoles of its derivative, statins, aspirin, warfarin, heparin, low molecular weight heparin and Xi Luo.
Preferably, in said medicine sacculus, the excipient is Iohexol, magnesium stearate, Iopromide, urea, poly- second
Glycol, polysorbate, D-sorbite, three hexyl citrate of bytyry, citroflex A-4, organic ester, shellac and
One or more of lauric acid.
Preferably, in said medicine sacculus, the medication coat with a thickness of 1-100um.
Preferably, in said medicine sacculus, the medication coat with a thickness of 2-50um.
Preferably, in said medicine sacculus, the sacculus is using nylon, modification of nylon, nylon elastomer and linear low close
Spend one or more of polyethylene different materials.
Preferably, in said medicine sacculus, the sacculus includes sequentially connected balloon proximal portion, sacculus middle portion and ball
Capsule distal portion, the proximal end coating is located at balloon proximal portion surface, the middle section coating is located at the sacculus middle portion table
Face, the distal end coating are located at balloon distal portion surface, and under pressurising state, the balloon proximal portion is remote with the sacculus
The diameter of one is greater than the diameter of the sacculus middle portion in end, and the diameter of another one is straight not less than the sacculus middle portion
Diameter.
Preferably, in said medicine sacculus, the balloon proximal portion includes sequentially connected balloon proximal portion proximal end, sacculus
Close end middle section and balloon proximal portion distal end, the diameter of balloon proximal portion proximal end is by separate balloon proximal portion middle section
One end is gradually increased to the other end.
Preferably, in said medicine sacculus, the balloon distal portion includes sequentially connected balloon distal portion proximal end, sacculus
Distal portion middle section and balloon distal portion distal end, the diameter of balloon distal portion distal end is by separate balloon distal portion middle section
One end is gradually increased to the other end.
Medicinal balloon provided by the utility model includes sacculus and medication coat, and medication coat is coated on balloon surface, packet
Include drug and excipient.Wherein, medication coat includes proximal end coating, the middle section coating positioned at sacculus middle section positioned at balloon proximal
With the distal end coating for being located at balloon distal.The load medicine for carrying medicine density and being greater than middle section coating of one in proximal end coating and distal end coating
Density, the load medicine density for carrying medicine density and being not less than middle section coating of another one.
In intrastent restenotic lesions, the vascular smooth muscle cell curing of mount proximal end and/or distal portions is the most serious,
Radial load from blood vessel is maximum.The load of one in medicinal balloon provided by the utility model, proximal end coating and distal end coating
Medicine density is greater than the load medicine density of middle section coating, the load medicine density for carrying medicine density and being not less than middle section coating of another one.Thus, root
Fed back according to iconography, judge serious restenosis occur in lesion proximal end or distal end one at or two at, select the utility model
In medicinal balloon carry out pressurising, emphasis regioselectivity is administered, at the serious change for guaranteeing mount proximal end and/or distal end
Medicament contg is relatively higher, more effectively inhibits smooth muscle cell hyperplasia, improves lumen patency rate at a specified future date, guarantees treatment effect
Fruit, while the total drug content of whole section of lesion is reduced, and then reduce body drug toxicity and adverse reaction.
Detailed description of the invention
In order to illustrate the embodiment of the utility model or the technical proposal in the existing technology more clearly, below will be to embodiment
Or attached drawing needed to be used in the description of the prior art is briefly described, it should be apparent that, the accompanying drawings in the following description is only
It is some embodiments of the utility model, for those of ordinary skill in the art, in the premise not made the creative labor
Under, it is also possible to obtain other drawings based on these drawings.
Fig. 1 (a)-(b) is the structural schematic diagram of medicinal balloon in the utility model embodiment one and embodiment two respectively；
Fig. 2 (a)-(b) is the structural schematic diagram of medication coat in the utility model embodiment one and embodiment two respectively；
Fig. 3 is the structural schematic diagram of medicinal balloon cross section in the utility model embodiment one and embodiment two；
Fig. 4 (a)-(b) is the structure of intrastent restenotic lesions in the utility model embodiment one and embodiment two respectively
Schematic diagram；
Fig. 5 (a)-(b) is in the utility model embodiment one and embodiment two respectively, and medicinal balloon is transported in bracket
Structural schematic diagram at restenotic lesions；
Fig. 6 (a)-(b) is the utility model embodiment one and embodiment two respectively, and medicinal balloon is in in-stent restenosis disease
Structural schematic diagram at change when pressurising.
It is marked in attached drawing as follows:
Medicinal balloon -1；Intrastent restenotic lesions -2；Sacculus -10；Medication coat -11；Proximal end coating -110；Middle section applies
Layer -111；Distal end coating -112；Drug -113；Excipient -114；Intrastent restenotic lesions proximal end -20；In-stent restenosis
Lesion middle section -21；Intrastent restenotic lesions distal end -22；The bracket -23 of original implantation.
Specific embodiment
The utility model embodiment discloses a kind of medicinal balloon, more effectively to inhibit mount proximal end and/or distal end flat
Sliding myocyte's hyperplasia improves lumen patency rate at a specified future date, guarantees therapeutic effect, while the drug for reducing whole section of lesion always contains
Amount, and then reduce body drug toxicity and adverse reaction.
The following will be combined with the drawings in the embodiments of the present invention, carries out the technical scheme in the embodiment of the utility model
Clearly and completely describe, it is clear that the described embodiments are only a part of the embodiments of the utility model, rather than whole
Embodiment.Based on the embodiments of the present invention, those of ordinary skill in the art are without making creative work
Every other embodiment obtained, fall within the protection scope of the utility model.It should be noted that attached drawing be all made of it is very simple
The form of change and use non-accurate ratio, only to it is convenient, lucidly aid in illustrating the purpose of the utility model embodiment.
The core concept of the application is to be improved by the structure to medicinal balloon, and different location medication coat is to lesion region
Selectivity administration.In use, fed back according to iconography, judge serious restenosis occur in lesion proximal end or distal end one at or
At two, select the utility model in medicinal balloon carry out pressurising, to emphasis regioselectivity be administered, guarantee mount proximal end and/
Or the medicament contg at the serious change of distal end is relatively higher, more effectively inhibits smooth muscle cell hyperplasia, improves at a specified future date
Lumen patency rate guarantees therapeutic effect, while reducing the total drug content of whole section of lesion, and then reduces body drug toxicity and not
Good reaction.
It is illustrated below with two specific embodiments.
Embodiment (one)
Please refer to Fig. 1 (a), 2 (a) and Fig. 3.Fig. 1 (a) is that the structure of medicinal balloon 1 in the utility model embodiment one is shown
It is intended to；Fig. 2 (a) is the structural schematic diagram of medication coat 11；Fig. 3 is the structural schematic diagram of 1 cross section of medicinal balloon.The implementation
In, medicinal balloon 1 includes sacculus 10 and medication coat 11.
Wherein, medication coat 11 is located at balloon surface, including drug 113 and excipient 114.Medication coat 11 includes proximal end
Coating 110, middle section coating 111 and distal end coating 112, and proximal end coating 110, middle section coating 111 and distal end coating 112 are sequentially arranged
Cloth connection, is distributed in the outer surface of sacculus 10.The load medicine that load medicine density in proximal end coating 110 is greater than in the coating of middle section 111 is close
It spends, the load medicine density for carrying medicine density and being greater than in middle section coating 111 in distal end coating 112.It should be noted that proximal end coating
110 and distal end coating 112 be located at the both ends of middle section coating 111, specific proximal end and distal end only for distinguishing middle section coating 111
Opposite both ends have no the restriction of absolute distant relationships.In this embodiment, the load medicine of proximal end coating 110 and distal end coating 112
Density is all larger than the load medicine density of middle section coating 111, and both specific load medicine density can be equal.It as needed, also include close
The load medicine density of end coating 110 and distal end coating 112 is all larger than the load medicine density of middle section coating 111, but the load medicine density of the two
It is unequal, to be suitable for the different situation of intrastent restenotic lesions both ends smooth muscle cell proliferation degree.In other embodiments
In, proximal end coating 110, middle section coating 111 and distal end coating 112 can also be in unconnected discontinuous structure.
Specifically, sacculus 10 uses nylon elastomer material.As needed, sacculus may be nylon, modification of nylon and
One or more of linear low density of polyethylene different materials.
Specifically, drug 113 is rapamycin in medication coat 11.As needed, or taxol, polyenoid are purple
In its azoles of China fir alcohol, rapamycin derivative, statins, aspirin, warfarin, heparin, low molecular weight heparin and Xi Luo
It is one or more of.
Specifically, excipient 114 is polysorbate in medication coat 11.As needed, or Iohexol, tristearin
Sour magnesium, Iopromide, urea, polyethylene glycol, D-sorbite, three hexyl citrate of bytyry, citroflex A-4,
One or more of organic ester, shellac and lauric acid
Specifically, the load medicine density of medication coat 11 is 0.1-9.0ug/mm in medication coat 112, preferably 0.5-
5.0ug/mm2, most preferably 2.0-4.0ug/mm2.It should be noted that proximal end coating 110, middle section coating 111 and distal end coating
112 should all meet above-mentioned numberical range, and the load medicine density for carrying medicine density and being greater than in the coating of middle section 111 in proximal end coating 110,
The load medicine density for carrying medicine density and being greater than in middle section coating 111 in distal end coating 112
Specifically, in medication coat 11, medication coat 11 with a thickness of 1-100um, preferably 2-50um, most preferably 5-
20um。
Said medicine sacculus 1, medication coat be by drug and one of excipient and tetrahydrofuran, ethyl alcohol and acetonitrile or
It is several to be mixed, mixed liquor is coated in balloon surface by way of spraying, dipping, drop, brushing, is obtained by air-drying
Medication coat.It can specifically be prepared by following manner.Drug 113 and excipient 114 are mixed with tetrahydrofuran, obtained
Mixed liquor.Mixed liquor is coated uniformly on to the surface of sacculus 10 first by way of spraying, carries medicine density by air-drying to obtain
Uniform medication coat.Then, one layer of mixed solution is sprayed again in uniform proximal end coating 110 and 112 surface of distal end coating, pass through
It crosses to air-dry and obtains the load medicine density that the medicine density of the load in proximal end coating 110 is greater than in middle section coating 111, in distal end coating 112
Carry the medicinal balloon 1 for the load medicine density that medicine density is greater than in middle section coating 111.Finally medicinal balloon 1 fold pressing and be held, taken turns
Wide state is in three wings.
Fig. 4 (a) is please referred to, is the structural schematic diagram of intrastent restenotic lesions 2.In bracket caused by the bracket 23 of implantation
Restenotic lesions 2 include: intrastent restenotic lesions proximal end 20, intrastent restenotic lesions middle section 21 and in-stent restenosis disease
Become distal end 22.Wherein, the smooth muscle cell proliferation of restenotic lesions proximal end 20 and restenotic lesions distal end 22 is more serious, and lumen is logical
Smooth rate is lower, and stenosis is bigger.
Fig. 5 (a) is please referred to, is transported to the structure in intrastent restenotic lesions 2 for the medicinal balloon 1 under contraction state
Schematic diagram.In target site, it is ensured that under contraction state, proximal end coating 110 is corresponding with restenotic lesions proximal end 20, middle section coating
111 is corresponding with restenotic lesions middle section 21, and distal end coating 112 is corresponding with restenotic lesions distal end 22.
Fig. 6 (a) is please referred to, to make it support the structural representation of intrastent restenotic lesions 2 to 1 pressurising of medicinal balloon
Figure.When to 1 pressurising of medicinal balloon, the amount for the drug 113 that proximal end coating 110 discharges when expanding to lesion proximal end 20 is bigger,
Has the function of stronger inhibition smooth muscle cell proliferation.After the completion of supporting and discharging drug, to 1 pressure release of medicinal balloon, by it
It withdraws from external.
Embodiment (two)
Please refer to Fig. 1 (b), 2 (b) and Fig. 3.Fig. 1 (b) is that the structure of medicinal balloon 1 in the utility model embodiment two is shown
It is intended to；Fig. 2 (b) is the structural schematic diagram of medication coat 11；Fig. 3 is the structural schematic diagram of the cross section of medicinal balloon 1.The implementation
In example, medicinal balloon 1 includes sacculus 10 and medication coat 11.
Wherein, medication coat 11 is located at balloon surface, including proximal end coating 110, middle section coating 111 and distal end coating 112,
And proximal end coating 110, middle section coating 111 and distal end coating 112 are sequentially arranged connection.Medication coat 11 includes drug 113 and assigns
Shape agent 114.Load medicine density of the medicine density greater than in the coating of middle section 111, the load in distal end coating 112 are carried in proximal end coating 110
Medicine density is equal to the load medicine density in middle section coating 111.In other embodiments, proximal end coating 110, middle section coating 111 and remote
Holding coating 112 can also be in unconnected discontinuous structure.
Specifically, sacculus 10 uses nylon material.As needed, sacculus can also use modification of nylon, nylon elastomer
One or more of with linear low density of polyethylene different materials.
Specifically, drug 113 is taxol in medication coat 11.As needed, drug may be Docetaxel,
One in rapamycin and its derivative, statins, aspirin, warfarin, heparin, low molecular weight heparin and Xi Luo its azoles
Kind is several.
Specifically, excipient 114 is polyethylene glycol in medication coat 11.As needed, excipient may be iodine sea
Alcohol, magnesium stearate, Iopromide, urea, polysorbate, D-sorbite, three hexyl citrate of bytyry, acetyl citrate
One or more of tributyl, organic ester, shellac and lauric acid.
Specifically, the load medicine density of medication coat 11 is 0.1-9.0ug/mm in medication coat 112, preferably 0.5-
5.0ug/mm2, most preferably 2.0-4.0ug/mm2。
Specifically, in medication coat 11, medication coat 11 with a thickness of 1-100um, preferably 2-50um, most preferably 5-
20um。
Said medicine sacculus 1 can specifically be prepared by following manner.By drug 113 and excipient 114 and tetrahydrofuran
It is mixed, obtains two kinds of different mixed liquors of medicament contg.Low concentration mixed liquor is uniformly applied first by way of spraying
Middle section and the distal surface of sacculus 10 are overlayed on, middle section coating 111 and distal end coating 112 are obtained.It then, will by way of spraying
High drug concentration mixed liquor is coated uniformly on the proximal end face of sacculus 10, obtains proximal end coating 110.Next, by medicinal balloon 1
It carries out air-drying processing, obtains the load medicine density that medicine density is greater than in middle section coating 111 of carrying in proximal end coating 110 and applied equal to distal end
The medicinal balloon 1 of the load medicine density of 112 kinds of layer.Finally medicinal balloon 1 fold pressing and be held, profile state is in six wings.
Fig. 4 (b) is please referred to, is the structural schematic diagram of intrastent restenotic lesions 2.In bracket caused by the bracket 23 of implantation
Restenotic lesions 2 include: intrastent restenotic lesions proximal end 20, intrastent restenotic lesions middle section 21 and in-stent restenosis disease
Become distal end 22.Wherein, the smooth muscle cell proliferation of restenotic lesions proximal end 20 is more serious, and lumen patency rate is lower, stenosis
It is bigger.
Fig. 5 (b) is please referred to, is transported to the structure in intrastent restenotic lesions 2 for the medicinal balloon 1 under contraction state
Schematic diagram.In target site, it is ensured that under contraction state, proximal end coating 110 is corresponding with restenotic lesions proximal end 20, middle section coating
111 is corresponding with restenotic lesions middle section 21, and distal end coating 112 is corresponding with restenotic lesions distal end 22.
Fig. 6 (b) is please referred to, to make it support the structural representation of intrastent restenotic lesions 2 to 1 pressurising of medicinal balloon
Figure.When to 1 pressurising of medicinal balloon, the amount for the drug 113 that proximal end coating 110 discharges when expanding to lesion proximal end 20 is bigger,
Has the function of stronger inhibition smooth muscle cell proliferation.After the completion of supporting and discharging drug, to 1 pressure release of medicinal balloon, by it
It withdraws from external.
In the above embodiments, sacculus includes sequentially connected balloon proximal portion, sacculus middle portion and balloon distal portion,
Sacculus includes sequentially connected balloon proximal portion, sacculus middle portion and balloon distal portion, and proximal end coating is located at balloon proximal portion table
Face, middle section coating are located at sacculus middle portion surface, distal end coating is located at balloon distal portion surface, and under pressurising state, sacculus is close
The diameter of one is greater than the diameter of sacculus middle portion in end and balloon distal portion, and the diameter of another one is not less than in the sacculus
The diameter in section portion.Diameter namely both including balloon proximal portion and balloon distal portion is all larger than the diameter of sacculus middle portion, and
The diameter of the two is equal；In other implementations, the diameter also including balloon proximal portion and balloon distal portion is all larger than sacculus middle section
The diameter in portion, but the diameter of the two is unequal；It further include that the diameter in balloon proximal portion is greater than the diameter of sacculus middle portion, sacculus is remote
The diameter of end is equal to the diameter of sacculus middle portion or the diameter in balloon proximal portion is equal to the diameter of sacculus middle portion, sacculus
The diameter of distal portion is greater than the diameter of sacculus middle portion, and then can be suitable for intrastent restenotic lesions both ends smooth muscle cell
The different situation of hyperplasia degree.According to balloon proximal portion, the difference of sacculus middle portion and balloon distal portion shape, if balloon proximal
The diameter in portion, sacculus middle portion or balloon distal portion changes, then the maximum gauge in balloon proximal portion and balloon distal portion is greater than
The maximum gauge of sacculus middle portion.Preferably, the company of smooth transition between balloon proximal portion, sacculus middle portion and balloon distal portion
It connects.
In intrastent restenotic lesions, the vascular smooth muscle cell curing of mount proximal end and/or distal portions is the most serious,
Radial load from blood vessel is maximum.The load of one in medicinal balloon provided by the utility model, proximal end coating and distal end coating
Medicine density is greater than the load medicine density of middle section coating, the load medicine density for carrying medicine density and being not less than middle section coating of another one.For right
Under the setting pressurising state answered, the diameter of one is greater than the diameter of sacculus middle portion in balloon proximal portion and balloon distal portion, separately
The diameter of one is not less than the diameter of the sacculus middle portion.Such as: in proximal end, the medicine density that carries of coating is greater than middle section coating
Medicine density is carried, when carrying load medicine density of the medicine density not less than middle section coating of distal end coating, the diameter in balloon proximal portion is greater than ball
The diameter of capsule middle portion, the diameter in balloon distal portion are not less than the diameter of sacculus middle portion.And then it on the one hand can be to emphasis area
Field selectivity administration guarantees that the medicament contg at the serious change of mount proximal end and/or distal end is relatively higher.On the other hand, it fills
Under pressure condition, sacculus is more powerful to the supporting role at proximal end or distal end Serious Stenosis, has stronger inhibition smooth muscle thin
The effect of born of the same parents' hyperplasia.
Specifically, balloon proximal portion includes that sequentially connected balloon proximal portion proximal end, balloon proximal portion middle section and sacculus are close
The diameter of end distal end, balloon proximal portion proximal end is gradually increased from one end far from balloon proximal portion middle section to the other end.Sacculus
The diameter of close end proximal end is from one end far from balloon proximal portion middle section to the other end (namely close to balloon proximal portion middle section
One end) it is gradually increased, it is preferred that it is gradually increased to equal with the diameter in balloon proximal portion middle section.Namely balloon proximal portion
End diameter is transition, consequently facilitating the movement of intervention sacculus.
Further, the profile of balloon proximal portion proximal end in skew lines shape, sine and cosine is linear, hyperbola, index are linear
Or logarithm is one of linear；Balloon proximal portion middle section is cylindrical or conical；The profile of balloon proximal portion distal end is in level
One of linear, skew lines shape, sine and cosine be linear, hyperbola, index are linear or logarithm is linear.
Further, sacculus middle portion is cylindrical or conical.
Specifically, balloon distal portion includes that sequentially connected balloon distal portion proximal end, balloon distal portion middle section and sacculus are remote
The diameter of end distal end, balloon distal portion distal end is gradually increased from one end far from balloon distal portion middle section to the other end.Also
The end diameter for being balloon distal portion 12 is transition, consequently facilitating the movement of intervention sacculus.
Further, balloon distal portion proximal end profile is linear in level, skew lines shape, sine and cosine is linear, hyperbola, refers to
The linear or logarithms of number are one of linear；Balloon distal portion middle section is cylindrical or conical；Balloon distal portion distal end profile is in
One of skew lines shape, sine and cosine be linear, hyperbola, index are linear or logarithm is linear.
To sum up, the medicinal balloon 1 for the treatment of in-stent restenosis is provided in the utility model including sacculus 10 and is located at ball
The medication coat 11 on capsule surface, medication coat 11 include proximal end coating 110, middle section coating 111 and distal end coating 112, all medicines
Object coating 11 includes drug 113 and excipient 114, during the load medicine density of one is greater than in proximal end coating 110 and distal end coating 112
Load medicine density in section coating 111, the load medicine density for carrying medicine density and being not less than middle section coating 111 of another one.
The technical solution of the application is designed by structure, processing and the application method to medicinal balloon, anti-according to iconography
Feedback, judge serious restenosis occur in lesion proximal end or distal end one at or two at, select the drug ball in the utility model
Capsule carries out pressurising, and emphasis regioselectivity is administered, and guarantees the medicament contg phase at the serious change of mount proximal end and/or distal end
To higher, more effectively inhibit smooth muscle cell hyperplasia, improves lumen patency rate at a specified future date, guarantee therapeutic effect, drop simultaneously
The total drug content of low whole section of lesion, and then reduce body drug toxicity and adverse reaction.
Each embodiment in this specification is described in a progressive manner, the highlights of each of the examples are with other
The difference of embodiment, the same or similar parts in each embodiment may refer to each other.
The foregoing description of the disclosed embodiments can be realized professional and technical personnel in the field or using originally practical new
Type.Various modifications to these embodiments will be readily apparent to those skilled in the art, and determine herein
The General Principle of justice can be realized in other embodiments without departing from the spirit or scope of the present utility model.Cause
This, the present invention will not be limited to the embodiments shown herein, and is to fit to and principles disclosed herein
The widest scope consistent with features of novelty.
Claims (7)
1. a kind of medicinal balloon, including sacculus and positioned at the medication coat of the balloon surface, the medication coat includes drug
And excipient；It is characterized in that, the medication coat includes proximal end coating, middle section coating and distal end coating, the proximal end coating
It is greater than the load medicine density of the middle section coating with the load medicine density of one in the distal end coating, the load medicine density of another one is not small
In the load medicine density of the middle section coating.
2. medicinal balloon according to claim 1, which is characterized in that the proximal end coating, the middle section coating and described
The connection of distal end coating order, is distributed in the sacculus outer surface.
3. medicinal balloon according to claim 2, which is characterized in that the medication coat with a thickness of 1-100um.
4. medicinal balloon according to claim 2, which is characterized in that the medication coat with a thickness of 2-50um.
5. medicinal balloon according to claim 1-4, which is characterized in that the sacculus includes sequentially connected ball
Capsule close end, sacculus middle portion and balloon distal portion, the proximal end coating are located at balloon proximal portion surface, the middle section and apply
Layer is located at sacculus middle portion surface, the distal end coating is located at balloon distal portion surface, and under pressurising state, described
The diameter of one is greater than the diameter of the sacculus middle portion in balloon proximal portion and the balloon distal portion, and the diameter of another one is not
Less than the diameter of the sacculus middle portion.
6. medicinal balloon according to claim 5, which is characterized in that the balloon proximal portion includes sequentially connected sacculus
Close end proximal end, balloon proximal portion middle section and balloon proximal portion distal end, the diameter of balloon proximal portion proximal end is by far from described
The one end in balloon proximal portion middle section is gradually increased to the other end.
7. medicinal balloon according to claim 5, which is characterized in that the balloon distal portion includes sequentially connected sacculus
Distal portion proximal end, balloon distal portion middle section and balloon distal portion distal end, the diameter of balloon distal portion distal end is by far from described
The one end in balloon distal portion middle section is gradually increased to the other end.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820640738.8U CN209137002U (en) | 2018-04-28 | 2018-04-28 | A kind of medicinal balloon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201820640738.8U CN209137002U (en) | 2018-04-28 | 2018-04-28 | A kind of medicinal balloon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN209137002U true CN209137002U (en) | 2019-07-23 |
Family
ID=67264761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201820640738.8U Active CN209137002U (en) | 2018-04-28 | 2018-04-28 | A kind of medicinal balloon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN209137002U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108378964A (en) * | 2018-04-28 | 2018-08-10 | 上海脉全医疗器械有限公司 | A kind of medicinal balloon |
| CN110882473A (en) * | 2019-12-26 | 2020-03-17 | 科睿驰（深圳）医疗科技发展有限公司 | Medicinal balloon catheter and preparation method thereof |
| EP4066878A4 (en) * | 2019-11-25 | 2024-01-10 | Qiwei Medical Tech Shenzhen Co Ltd | Balloon assembly and medical device comprising same |
-
2018
- 2018-04-28 CN CN201820640738.8U patent/CN209137002U/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108378964A (en) * | 2018-04-28 | 2018-08-10 | 上海脉全医疗器械有限公司 | A kind of medicinal balloon |
| EP4066878A4 (en) * | 2019-11-25 | 2024-01-10 | Qiwei Medical Tech Shenzhen Co Ltd | Balloon assembly and medical device comprising same |
| CN110882473A (en) * | 2019-12-26 | 2020-03-17 | 科睿驰（深圳）医疗科技发展有限公司 | Medicinal balloon catheter and preparation method thereof |
| CN110882473B (en) * | 2019-12-26 | 2022-04-15 | 科睿驰（深圳）医疗科技发展有限公司 | Medicinal balloon catheter and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN209137002U (en) | A kind of medicinal balloon | |
| DE69729778T2 (en) | Stent for the dilation of stenotic damage of a blood vessel | |
| CN111298272A (en) | Drug-coated balloon, preparation method thereof and drug-coated balloon dilatation catheter | |
| CN107308536A (en) | Include the foley's tube of drug delivery sheath | |
| CN106237395B (en) | A kind of medicine-coated balloon and preparation method thereof | |
| JP5777607B2 (en) | H-side branch vessel stent | |
| KR20040066409A (en) | Stent for percutaneous coronary intervention coated with drugs for the prevention of vascular restenosis | |
| CN108378964A (en) | A kind of medicinal balloon | |
| CN209790103U (en) | Drug release device for blood vessel saccule and saccule support | |
| CN108498208B (en) | Blood vessel support suitable for artery blood vessel | |
| CN104857615A (en) | Novel dual-layer drug balloon catheter | |
| CN110548212B (en) | Double-balloon catheter with self-perfusion function | |
| CN104174073B (en) | A kind of medicine-carrying method of medicine eluting balloon catheter | |
| CN205198665U (en) | Sacculus expansion pipe of double -deck hypo pipe | |
| Moore et al. | Use of an intravascular endoprosthesis (stent) to establish and maintain short-term patency of the ductus arteriosus in newborn lambs | |
| CN106137486A (en) | A kind of bifurcated sacculus | |
| CN202191582U (en) | Medicine balloon dilating catheter | |
| CN105853036B (en) | A kind of degradable personalized bionical medicament elution coronary stent of non-columnar | |
| CN204840623U (en) | Medicine elution sacculus | |
| Parsons et al. | Balloon dilatation of a stenosed modified (polytetrafluoroethylene) Blalock-Taussig shunt. | |
| CN107995869B (en) | Surface liquefied drug coating sacculus | |
| CN106178138A (en) | A kind of medicinal balloon | |
| CN203935501U (en) | A kind of medicinal balloon catheter | |
| CN205054514U (en) | Blood vessel bracket | |
| CN206007415U (en) | A kind of bionical medicament elution coronary stent of the personalized non-columnar of degradable |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |